Physiomics (GB:PYC) has released an update.
Physiomics plc has secured a new contract worth £161,580 with a leading UK biotech company, leveraging their Virtual Tumour technology to optimize oncology treatment dosing regimens. The project is expected to span five months and marks the start of a collaboration that could extend into future programs, highlighting Physiomics’ role in supporting novel therapy development with its data science expertise.
For further insights into GB:PYC stock, check out TipRanks’ Stock Analysis page.
